Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Randomized Double-Blind Study of Tucatinib vs Placebo with Capecitabine and Trastuzumab in HER2-positive Metastatic Breast Cancer
2015-002801-12Phase 2Completed
- Sponsor
- Seagen Inc.
- Start
- Mar 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in breast cancer comparing Tucatinib Arm with Placebo Arm (2 arms). Primary endpoint: Progression Free Survival. Started Mar 2017; status: completed.
02
Drugs
tucatinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2015-002801-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002801-12.